CDR1as interacts with the Insulin-like growth factor-binding protein 3 (IGF2BP3); its silencing activates IGF2BP3 and promotes melanoma invasion, resistance to GPX4 inhibitors, and tumor growth in vivo [124]. The gene discussed is LINC00632; the disease is neoplasm.